Last reviewed · How we verify
Standard-of-care SARS-CoV-2 treatment
Standard-of-care SARS-CoV-2 treatment is a Nucleotide analog Small molecule drug developed by Chita State Regional Clinical Hospital Number 1. It is currently in Phase 3 development for Treatment of COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) requiring hospitalization and oxygen therapy.
Remdesivir is an antiviral medication that works by inhibiting the replication of the SARS-CoV-2 virus.
Remdesivir is an antiviral medication that works by inhibiting the replication of the SARS-CoV-2 virus. Used for Treatment of COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) requiring hospitalization and oxygen therapy.
At a glance
| Generic name | Standard-of-care SARS-CoV-2 treatment |
|---|---|
| Sponsor | Chita State Regional Clinical Hospital Number 1 |
| Drug class | Nucleotide analog |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
Remdesivir is a nucleotide analog that acts as a chain terminator during viral RNA synthesis, thereby preventing the virus from replicating. This mechanism of action is specific to the SARS-CoV-2 virus and is not effective against other types of viruses.
Approved indications
- Treatment of COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) requiring hospitalization and oxygen therapy
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
- Headache
- Fatigue
- Increased liver enzymes
- Anemia
- Thrombocytopenia
- Neutropenia
Key clinical trials
- I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients (PHASE2)
- Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia (PHASE3)
- OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients (PHASE2)
- Impact of Telemonitoring in the Management of Complex IBD in Spain: M-TECCU (NA)
- The COVID-RASi Trial (COVID-19) (PHASE3)
- Fast Track to Fertility (NA)
- Outpatient Treatment With Anti-Coronavirus Immunoglobulin (PHASE3)
- AGILE (Early Phase Platform Trial for COVID-19) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard-of-care SARS-CoV-2 treatment CI brief — competitive landscape report
- Standard-of-care SARS-CoV-2 treatment updates RSS · CI watch RSS
- Chita State Regional Clinical Hospital Number 1 portfolio CI
Frequently asked questions about Standard-of-care SARS-CoV-2 treatment
What is Standard-of-care SARS-CoV-2 treatment?
How does Standard-of-care SARS-CoV-2 treatment work?
What is Standard-of-care SARS-CoV-2 treatment used for?
Who makes Standard-of-care SARS-CoV-2 treatment?
What drug class is Standard-of-care SARS-CoV-2 treatment in?
What development phase is Standard-of-care SARS-CoV-2 treatment in?
What are the side effects of Standard-of-care SARS-CoV-2 treatment?
Related
- Drug class: All Nucleotide analog drugs
- Manufacturer: Chita State Regional Clinical Hospital Number 1 — full pipeline
- Therapeutic area: All drugs in Infectious Diseases
- Indication: Drugs for Treatment of COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) requiring hospitalization and oxygen therapy
- Compare: Standard-of-care SARS-CoV-2 treatment vs similar drugs
- Pricing: Standard-of-care SARS-CoV-2 treatment cost, discount & access